Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

• Mario Sznol,
• Adi Diab,
• Jonathan Zalevsky,
• Ute Hoch,
• Mehmet A Bilen,
• Giovanni Grignani,
• Nizar M Tannir,
• Erika Puente,
• Arjun V Balar,
• Daniel C Cho,
• Arlene O Siefker-Radtke,
• Lily Tang,
• David Chien,
• Arkopal Choudhury,
• Danni Yu,
• Sue L Currie,
• Mary A Tagliaferri,
• Michael E Hurwitz

Affiliations

Mario Sznol

Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA

Adi Diab

Melanoma Medical Onoclogy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Jonathan Zalevsky

Nektar Therapeutics, San Francisco, California, USA

Ute Hoch

12Nektar Therapeutics, San Francisco, CA, USA

Mehmet A Bilen

Winship Cancer Institute of Emory University, Atlanta, Georgia, USA

Giovanni Grignani

Division of Medical Oncology, Candiolo Cancer Institute - FPO, IRCCS, Torino, Italy

Nizar M Tannir

Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA

Erika Puente

12Nektar Therapeutics, San Francisco, CA, USA

Arjun V Balar

Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York, USA

Daniel C Cho

Department of Medicine, Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York, USA

Arlene O Siefker-Radtke

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Lily Tang

Elpiscience Biopharmaceuticals, Shanghai, China

David Chien

Nektar Therapeutics, San Francisco, California, USA

Arkopal Choudhury

Nektar Therapeutics, San Francisco, California, USA

Danni Yu

Nektar Therapeutics, San Francisco, California, USA

Sue L Currie

Nektar Therapeutics, San Francisco, California, USA

Mary A Tagliaferri

Nektar Therapeutics, San Francisco, California, USA

Michael E Hurwitz

Yale Cancer Center, New Haven, Connecticut, USA